eTheRNA opens mRNA manufacturing facility in Belgium to support production of mRNA cancer immunotherapies

eTheRNA immunotherapies, a clinical─stage company developing novel cancer immunotherapies based on its proprietary mRNA─based TriMix platform, announces the opening of a state─of─the─art mRNA manufacturing

More From BioPortfolio on "eTheRNA opens mRNA manufacturing facility in Belgium to support production of mRNA cancer immunotherapies"